Matthew W. Foehr net worth and biography

Matthew Foehr Biography and Net Worth

Matthew W. Foehr, has been our President and Chief Operating Officer since January 2015. Prior to that time, Mr. Foehr served as our Executive Vice President and Chief Operating Officer since 2011, and has more than 20 years of experience managing global research and development programs. Prior to joining our company in 2011, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline (GSK). Following GSK’s $3.6 billion acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from February 2015 until its merger with Qualigen Therapeutics, Inc. in May 2020. Mr. Foehr is the author of multiple scientific publications and is named on numerous U.S. patents. He received his B.S. degree in biology from Santa Clara University.

What is Matthew W. Foehr's net worth?: The estimated net worth of Matthew W. Foehr is at least $405.44 million as of May 24th, 2024. Mr. Foehr owns 3,536,665 shares of Ligand Pharmaceuticals stock worth more than $405,443,276 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Foehr may own. Learn More about Matthew W. Foehr's net worth.
How do I contact Matthew W. Foehr?: The corporate mailing address for Mr. Foehr and other Ligand Pharmaceuticals executives is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. Ligand Pharmaceuticals can also be reached via phone at (858) 550-7500 and via email at [email protected]. Learn More on Matthew W. Foehr's contact information.
Has Matthew W. Foehr been buying or selling shares of Ligand Pharmaceuticals?: Matthew W. Foehr has not been actively trading shares of Ligand Pharmaceuticals over the course of the past ninety days. Most recently, on Friday, May 13th, Matthew W. Foehr bought 2,500 shares of Ligand Pharmaceuticals stock. The stock was acquired at an average cost of $82.76 per share, with a total value of $206,900.00. Following the completion of the transaction, the chief operating officer now directly owns 173,354 shares of the company's stock, valued at $14,346,777.04. Learn More on Matthew W. Foehr's trading history.
Who are Ligand Pharmaceuticals' active insiders?: Ligand Pharmaceuticals' insider roster includes Matthew Foehr (COO), and John Higgins (CEO). Learn More on Ligand Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ligand Pharmaceuticals?: During the last year, Ligand Pharmaceuticals insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $243,475.00. During the last year, insiders at the biotechnology company sold shares 16 times. They sold a total of 81,455 shares worth more than $7,857,110.70. The most recent insider tranaction occured on November, 27th when Director John L Lamattina sold 2,406 shares worth more than $297,501.90. Insiders at Ligand Pharmaceuticals own 5.9% of the company. Learn More about insider trades at Ligand Pharmaceuticals.
Information on this page was last updated on 11/27/2024.

Matthew W. Foehr Insider Trading History at Ligand Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/13/2022	Buy	2,500	$82.76	$206,900.00	173,354
11/11/2021	Sell	11,160	$163.02	$1,819,303.20
8/4/2021	Sell	8,840	$109.67	$969,482.80	173,195
2/4/2021	Sell	44,547	$176.86	$7,878,582.42	167,198
8/24/2020	Sell	78	$110.89	$8,649.42	155,413
8/21/2020	Sell	7,225	$112.88	$815,558.00	155,413
2/27/2020	Buy	7,225	$14.47	$104,545.75	160,968
2/27/2020	Buy	1,706	$21.92	$37,395.52	155,449
2/27/2020	Sell	7,225	$110.00	$794,750.00	160,968
2/15/2020	Sell	869	$97.23	$84,492.87	155,360
2/15/2020	Sell	447	$97.23	$43,461.81	154,913
2/15/2020	Sell	1,170	$97.23	$113,759.10	153,743
2/14/2020	Buy	7,225	$14.47	$104,545.75	163,454
2/14/2020	Sell	7,225	$95.84	$692,444.00	148,833
2/13/2020	Buy	496	$21.92	$10,872.32	148,833
2/13/2020	Buy	7,396	$0.00	$0.00	156,229
10/1/2018	Sell	12,000	$273.88	$3,286,560.00	105,388
9/4/2018	Sell	12,000	$255.01	$3,060,120.00	103,300
5/10/2018	Sell	8,881	$167.63	$1,488,722.03	110,082
2/23/2018	Sell	5,444	$152.98	$832,823.12	95,835
8/9/2017	Sell	6,100	$127.51	$777,811.00	101,020
5/12/2017	Sell	5,621	$112.20	$630,676.20	98,341
3/2/2017	Sell	6,879	$103.39	$711,219.81	97,599
3/17/2016	Sell	6,400	$96.70	$618,880.00	83,062
6/26/2015	Sell	12,500	$100.97	$1,262,125.00
6/22/2015	Sell	23,046	$96.45	$2,222,786.70
6/28/2013	Buy	1,059	$17.36	$18,384.24

Matthew W. Foehr Buying and Selling Activity at Ligand Pharmaceuticals

Ligand Pharmaceuticals Company Overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Today's Range

Now: $114.64

$111.00

$115.47

50 Day Range

MA: $115.47

$103.46

$129.90

2 Week Range

Now: $114.64

$67.53

$129.90

Volume

551,595 shs

Average Volume

136,360 shs

Market Capitalization

$2.17 billion

P/E Ratio

45.67

Dividend Yield

N/A

Beta

1.01

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.